Literature DB >> 3785441

Increase in plasma catecholamines by intraventricular injection of histamine in conscious rats.

A O Donoso, M Barontini.   

Abstract

Intraventricular administration of histamine (HA; 2.5 and 5 micrograms) caused a significant increase of plasma adrenaline and noradrenaline levels in conscious, freely-moving male rats. The increase of adrenaline was more rapid (5 min after injection) and greater than that of noradrenaline. The plasma adrenaline increase observed 15 min after HA administration was dose-dependent. In contrast, plasma noradrenaline increased maximally in response to the low dose and reached similar values after the largest dose studied. Receptor mediation was examined by means of selective HA antagonists. Pretreatment with mepyramine blunted the adrenaline response at 15 min which suggests mediation at H1 receptors. In contrast, it was ineffective on plasma adrenaline at 5 min and plasma noradrenaline increase. Ranitidine, an H2-receptor antagonist, did not modify adrenaline response but enhanced the HA-induced increase of plasma noradrenaline. These findings suggest that HA activates the central drive to the adrenal medulla and to the peripheral sympathetic system. A participation of peripheral catecholamine secretion in the acute cardiovascular changes induced in rats by centrally injected HA is postulated.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3785441     DOI: 10.1007/bf00505820

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  29 in total

1.  Absorption of histamine into the blood stream on perfusion of the cerebral ventricles, and its uptake by brain tissue.

Authors:  M DRASKOCI; W FELDBERG; K FLEISCHHAUER; P S HARANATH
Journal:  J Physiol       Date:  1960-01       Impact factor: 5.182

2.  Modification of arterial blood pressure in rats following microinjection of drugs into the posterior hypothalamus.

Authors:  H E Brezenoff; D J Jenden
Journal:  Int J Neuropharmacol       Date:  1969-12

3.  Peripheral vascular effects of histamine administered into the cerebral ventricles of anaesthetized cats.

Authors:  T White
Journal:  Experientia       Date:  1965-03-15

Review 4.  Regulation of the adrenal medulla.

Authors:  A Ungar; J H Phillips
Journal:  Physiol Rev       Date:  1983-07       Impact factor: 37.312

5.  Histamine-elicited drinking is dependent upon gastric vagal afferents and peripheral angiotensin II in the rat.

Authors:  F S Kraly; L A Miller
Journal:  Physiol Behav       Date:  1982-05

6.  Control of circulation by cerebral catecholaminergic and histaminergic mechanisms.

Authors:  H Karppanen
Journal:  Acta Med Scand Suppl       Date:  1982

7.  Histamine-containing neurons in the rat hypothalamus.

Authors:  P Panula; H Y Yang; E Costa
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

8.  Some in vitro and in vivo actions of the new histamine H2-receptor antagonist, ranitidine.

Authors:  M J Daly; J M Humphray; R Stables
Journal:  Br J Pharmacol       Date:  1981-01       Impact factor: 8.739

9.  Central pressor activity of cimetidine in spontaneously hypertensive rats.

Authors:  N K Dadkar; V A Aroskar; R D Gupte; A N Dohadwalla
Journal:  J Pharm Pharmacol       Date:  1984-07       Impact factor: 3.765

10.  Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor.

Authors:  J M Arrang; M Garbarg; J C Schwartz
Journal:  Nature       Date:  1983-04-28       Impact factor: 49.962

View more
  2 in total

1.  Early postnatal treatment with propranolol affects development of brain amines and behavior.

Authors:  L A Hilakivi; T Taira; I Hilakivi; E MacDonald; L Tuomisto; K Hellevuo
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

2.  Involvement of the sympathetic nervous system in the reversal of critical haemorrhagic hypotension by endogenous central histamine in rats.

Authors:  Jerzy Jochem
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-28       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.